For patients with heparin-induced thrombocytopenia (HIT), reexposure to heparin is
generally not recommended. However, these patients are likely to require anticoagulation …

INTRODUCTION Heparin-induced thrombocytopenia (HIT) presents a unique situation:
heparin causes the very complications that its use was intended to prevent, for example …

BACKGROUND: Prognostic factors for unfavorable clinical outcome in patients with heparin-
induced thrombocytopenia (HIT) are largely unknown. DESIGN AND METHODS: In this …

Heparin-induced thrombocytopenia (HIT) is a serious complication of heparin therapy that
has a high rate of morbidity (thrombosis and amputation) and mortality. In the past, a number …

Several counterintuitive treatment paradoxes complicate the management of immune
heparin-induced thrombocytopenia (HIT). For example, simple discontinuation of heparin …

Thrombocytopenia is a relatively frequent and usually benign clinical complication of
heparin therapy. However, some patients receiving heparin and heparin-based products …

Heparin-induced thrombocytopenia (HIT) is a potentially devastating complication of therapy
with either unfractionated or low-molecular-weight heparin. Thrombocytopenia is no longer …

This chapter about the recognition, treatment, and prevention of heparin-induced
thrombocytopenia (HIT) is part of the Seventh ACCP Conference on Antithrombotic and …

Heparin-induced thrombocytopenia (HIT) is an immune-mediated disorder caused by the
development of antibodies to platelet factor 4 (PF4) and heparin. The thrombocytopenia is …

Introduction: Heparin-induced thrombocytopenia (HIT) is a drug-mediated, prothrombotic
disorder caused by immunization against platelet factor 4 (PF4) after complex formation with …